Literature DB >> 20075937

Perforin deficiency and susceptibility to cancer.

A J Brennan1, J Chia, J A Trapani, I Voskoboinik.   

Abstract

Cytotoxic lymphocytes (CLs) are the killer cells that destroy intracellular pathogen-infected and transformed cells, predominantly through the cytotoxic granule-mediated death pathway. Soluble cytotoxic granule components, including pore-forming perforin and pro-apoptotic serine proteases, granzymes, synergize to induce unscheduled apoptosis of the target cell. A complete loss of CL function results in an aggressive immunoregulatory disorder, familial hemophagocytic lymphohistiocytosis, whereas a partial loss of function seems to be a factor strongly predisposing to hematological malignancies. This review discusses the pathological manifestations of CL deficiencies due to impaired perforin function and describes novel aspects of perforin biology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20075937     DOI: 10.1038/cdd.2009.212

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  25 in total

Review 1.  Intestinal inflammation and colorectal cancer: a double-edged sword?

Authors:  Angelamaria Rizzo; Francesco Pallone; Giovanni Monteleone; Massimo Claudio Fantini
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

Review 2.  Perforin and granzymes: function, dysfunction and human pathology.

Authors:  Ilia Voskoboinik; James C Whisstock; Joseph A Trapani
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

3.  Structural and functional analysis of perforin mutations in association with clinical data of familial hemophagocytic lymphohistiocytosis type 2 (FHL2) patients.

Authors:  Omer An; Attila Gursoy; Aytemiz Gurgey; Ozlem Keskin
Journal:  Protein Sci       Date:  2013-06       Impact factor: 6.725

Review 4.  Granzyme M: behind enemy lines.

Authors:  S A H de Poot; N Bovenschen
Journal:  Cell Death Differ       Date:  2014-01-10       Impact factor: 15.828

5.  Heterozygosity for the common perforin mutation, p.A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals.

Authors:  Imran G House; Kevin Thia; Amelia J Brennan; Richard Tothill; Alexander Dobrovic; Wei Z Yeh; Richard Saffery; Zac Chatterton; Joseph A Trapani; Ilia Voskoboinik
Journal:  Immunol Cell Biol       Date:  2015-03-17       Impact factor: 5.126

Review 6.  Perforin: An intriguing protein in allograft rejection immunology (Review).

Authors:  Ana-Maria Pașatu-Cornea; Elena Ciciu; Liliana-Ana Tuță
Journal:  Exp Ther Med       Date:  2022-06-15       Impact factor: 2.751

7.  Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function.

Authors:  Megan L Ives; Cindy S Ma; Umaimainthan Palendira; Anna Chan; Jacinta Bustamante; Stephanie Boisson-Dupuis; Peter D Arkwright; Dan Engelhard; Diana Averbuch; Klaus Magdorf; Joachim Roesler; Jane Peake; Melanie Wong; Stephen Adelstein; Sharon Choo; Joanne M Smart; Martyn A French; David A Fulcher; Matthew C Cook; Capucine Picard; Anne Durandy; Miyuki Tsumura; Masao Kobayashi; Gulbu Uzel; Jean-Laurent Casanova; Stuart G Tangye; Elissa K Deenick
Journal:  J Allergy Clin Immunol       Date:  2013-07-04       Impact factor: 10.793

8.  An A91V SNP in the perforin gene is frequently found in NK/T-cell lymphomas.

Authors:  Rebeca Manso; Socorro María Rodríguez-Pinilla; Luis Lombardia; Gorka Ruiz de Garibay; Maria Del Mar López; Luis Requena; Lydia Sánchez; Margarita Sánchez-Beato; Miguel Ángel Piris
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

9.  Perforin and hematological cancer.

Authors:  Dimas Tadeu Covas
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 10.  Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.

Authors:  Pablo A González; Leandro J Carreño; Pablo F Céspedes; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Clin Dev Immunol       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.